Objective: To evaluate the clinical efficacy of pioglitazone and estriol combined with progesterone in the treatment of obese patients with polycystic ovary syndrome (PCOS). Methods: From January 2013 to December 2017, 98 patients with obesity PCOS were randomly divided into control group (n=49, estriol propropyl progesterone treatment)and observation group(n=49, estriol propionic progesterone+pioglitazone treatment),improvement of sex hormone and serum retinol binding protein 4 (RBP-4) were observed.Results: After treatment, the levels of luteinizing hormone (LH),follicle stimulating hormone (FSH), testosterone (T) and RBP-4 in the observation group were significantly lower than those in the control group, and Estradiol (E2) was higher than that in the control group(P<0.05);After treatment, the levels of Body mass index (BMI),fasting blood glucose (FPG), triglyceride (TG), total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C)in the observation group were significantly lower than those in the control group(P<0.05), and the level of high density lipoprotein cholesterol (HDL-C) was significantly higher than that in the control group(P<0.05); The total incidence of adverse reactions in the observation group was 6.12%, which was significantly lower than that of the control group (20.41%,P<0.05). The ovulation rate and pregnancy rate were 85.71% and 34.69%, respectively, which were significantly higher than those of the control group, 61.22% and 20.41%(P<0.05). Conclusion: Estriol and progesterone combined with pioglitazone can effectively reduce the level of sex hormones and RBP-4 in obese PCOS patients, improve the metabolic state, whose overall curative effect is ideal. |
[1] 张晓晨,崔璨.多囊卵巢综合征患者GLP-1、Ghrelin、Obestatin的变化[J].东南大学学报(医学版),2016,35(2):275-278.
[2] 宋艳丽,孙自学,卫爱武.二甲双胍对多囊卵巢综合征大鼠血清中网膜素-1水平的影响[J].东南大学学报(医学版),2019,38(1):23-27.
[3] 邓小艳,胡雅君,周海燕,等.达因-35对不同类型多囊卵巢综合征的疗效分析[J].生殖与避孕,2015,35(2):86-90.
[4] FU H,QIU Y,WEI F,et al.Spleen-Yang-deficiency patients with polycystic ovary syndrome have higher levels of visfatin[J].J Tradit Chin Med,2014,34(1):42-47.
[5] 徐文迪,陶弢,刘伟.多囊卵巢综合征代谢异常治疗新进展[J].上海交通大学学报(医学版),2015,35(9):1407-1413.
[6] 韦娟冰.来曲唑用于多囊卵巢综合征患者促排卵的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(19):1928-1930.
[7] 李荔,莫蕙,文斌,等.针灸联合二甲双胍治疗肥胖型多囊卵巢综合征不孕症的临床研究[J].中华中医药杂志,2014,29(7):2115-2119.
[8] QIU L,LIU J,HEI Q.Association between two polymorphisms of follicle stimulating hormone receptor gene and susceptibility to polycystic ovary syndrome:a meta-analysis[J].Chin Med Sci J,2015,30(1):44-50.
[9] 张添松,邹先翔,苏淑军,等.内脏脂肪素和二甲双胍对多囊卵巢综合征大鼠胰岛素抵抗和生殖内分泌的治疗作用[J].南方医科大学学报,2014,34(9):1314-1318.
[10] 邹晖.二甲双胍联合炔雌醇环丙孕酮治疗多囊卵巢综合征不孕症的效果[J].广东医学,2014,35(16):2614-2616.
[11] YU J,YU C,CAO Q,et al.Consensus on the integrated traditional Chinese and Western medicine criteria of diagnostic classification in polycystic ovary syndrome(draft)[J].J Integr Med,2017,15(2):102-109.
[12] 林微,李书艳,冯卫群.二甲双胍联合炔雌醇环丙孕酮片治疗多囊卵巢综合征的疗效及对相关激素分泌水平的影响[J].广东医学,2014,35(5):763-764.
[13] 孔冬冬,邸莎,马淑然,等.中医药治疗多囊卵巢综合征方剂用药规律分析[J].中国实验方剂学杂志,2015,21(23):202-206.
[14] 陈雅,叶碧绿,郑九嘉,等.血清及卵泡液抗苗勒管激素在多囊卵巢综合征患者体外受精促排卵治疗中的价值[J].中国临床药理学与治疗学,2015,20(12):1405-1411.
[15] 徐芳,侯丽辉,郝松莉,等.多囊卵巢综合征代谢组学研究进展[J].中国实用妇科与产科杂志,2016,32(5):489-494.
[16] 王情,冯艳婕,张仙儒,等.血清总睾酮/双氢睾酮值对多囊卵巢综合征合并肥胖的临床诊断意义[J].现代医学,2016,44(12):1726-1729. |